Efficacy and Safety of Nemtabrutinib (MK-1026) in Participants With Hematologic Malignancies (MK-1026-003)

Required: TP53 mutation

CLL/SLL participants with 17p deletion or tumor protein p53 (TP53) mutation who are relapsed or refractory following at least 1 line of prior therapy

Required: CCND1 overexpression

Mantle-cell lymphoma (MCL), documented by either overexpression of cyclin D1 or t (11;14)

Required: IGH t(11;14)

Mantle-cell lymphoma (MCL), documented by either overexpression of cyclin D1 or t (11;14)

Must have received: covalent irreversible BTK inhibitor — relapsed or refractory

relapsed or refractory to prior therapy with a covalent, irreversible Bruton's tyrosine kinase inhibitor (BTKi)

Must have received: BCL2 inhibitor — relapsed or refractory

relapsed or refractory to prior therapy with a ... B-cell lymphoma 2 inhibitor (BCL2i)

Must have received: PI3K inhibitor — failed, intolerant, or ineligible

must have received and failed, been intolerant to, or determined by their treating physician to be a poor phosphoinositide 3-kinase inhibitor (PI3Ki) candidate or ineligible for a PI3Ki per local guidelines

Must have received: chemoimmunotherapy — relapsed or refractory

relapsed or are refractory to chemoimmunotherapy

Must have received: anti-CD20-based regimen — relapsed or refractory

relapsed or refractory to at least one prior line of systemic therapy including an anti-CD20-based regimen

Must have received: immunomodulatory agent (lenalidomide) — relapsed or refractory

relapsed or refractory to chemoimmunotherapy and immunomodulatory agents (such as lenalidomide based regimen)

Cannot have received: systemic anti-cancer therapy

Has received prior systemic anti-cancer therapy within 5 half-lives or 4 weeks (if prior therapy was a monoclonal antibody) before C1D1